Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
TG Therapeutics, Inc. (TGTX) had Stock-Based Compensation of $31.33M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$141.15M |
|
$28.19M |
|
$18.94M |
|
$122.21M |
|
$106.31M |
|
$34.84M |
|
$-3.92M |
|
$30.92M |
|
$30.92M |
|
$28.19M |
|
$28.19M |
|
$28.19M |
|
$28.19M |
|
$34.84M |
|
$33.92M |
|
146.74M |
|
162.56M |
|
$0.19 |
|
$0.17 |
|
| Balance Sheet Financials | |
$663.96M |
|
-- |
|
$38.65M |
|
$702.61M |
|
$171.89M |
|
$245.04M |
|
$254.29M |
|
$426.18M |
|
$276.43M |
|
$276.43M |
|
$276.43M |
|
158.03M |
|
| Cash Flow Statement Financials | |
$-21.28M |
|
$-16.93M |
|
$-12.54M |
|
$181.19M |
|
$130.44M |
|
$-50.75M |
|
|
Stock-Based Compensation |
$31.33M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.86 |
|
-- |
|
-- |
|
0.47 |
|
0.89 |
|
86.58% |
|
24.69% |
|
24.69% |
|
-- |
|
21.91% |
|
19.97% |
|
$-21.35M |
|
-- |
|
-- |
|
-- |
|
0.20 |
|
0.12 |
|
0.61 |
|
147.62 |
|
10.20% |
|
10.20% |
|
4.01% |
|
5.41% |
|
$1.75 |
|
$-0.13 |
|
$-0.13 |
|